Clinical Updates – Page 8

Pirtobrutinib Demonstrates Superior Efficacy and Tolerability in cBTKi-Pretreated CLL/SLL: Insights from the BRUIN CLL-321 Phase III Trial

By MedXY 08/01/2025

Pirtobrutinib significantly improves progression-free survival and tolerability over standard regimens in covalent BTK inhibitor-pretreated CLL/SLL, offering a promising new option for this challenging population.

Clinical Updates Medical News

Lipoprotein(a) as an Independent Predictor of Peripheral Artery Disease and Carotid Stenosis: Insights from a Large UK Biobank Study

By MedXY 08/01/2025

A landmark UK Biobank study demonstrates that elevated lipoprotein(a) independently predicts both the onset and progression of peripheral artery disease and carotid stenosis, beyond traditional cardiovascular risk factors.

Clinical Updates Wellness & Lifestyle

Cilta-Cel CAR-T療法で再発・難治性多発性骨髄腫の長期予後：患者の3分の1が5年以上の寛解を達成

By MedXY 08/01/2025

最近のJ Clin Oncol研究では、cilta-cel治療を受けたRRMM患者の約33%が5年以上の無増悪生存を達成し、持続的な反応と有望なバイオマーカーが示されました。

$Long-Term Outcomes of Cilta-Cel CAR-T Therapy in Relapsed/Refractory Multiple Myeloma: Five-Year Remission Achieved in One-Third of Patients$

Clinical Updates Medical News

Long-Term Outcomes of Cilta-Cel CAR-T Therapy in Relapsed/Refractory Multiple Myeloma: Five-Year Remission Achieved in One-Third of Patients

By MedXY 08/01/2025

A recent J Clin Oncol study shows that nearly 33% of RRMM patients treated with cilta-cel achieved ≥5 years of progression-free survival, highlighting durable responses and promising biomarkers.

Clinical Updates Medical News

Efruxifermin for Compensated Liver Cirrhosis in MASH: Phase 2b Results and Clinical Implications

By MedXY 08/01/2025

A phase 2b trial found that efruxifermin did not significantly improve fibrosis at 36 weeks in patients with compensated cirrhosis due to MASH, though longer-term benefit was suggested at 96 weeks.

Clinical Updates Wellness & Lifestyle

First-Line Encorafenib, Cetuximab, and mFOLFOX6 in BRAF V600E–Mutated Metastatic Colorectal Cancer: Clinical Impact from the BREAKWATER Trial

By MedXY 08/01/2025

Combination therapy with encorafenib, cetuximab, and mFOLFOX6 significantly improves progression-free and overall survival compared to standard care in first-line treatment of BRAF V600E–mutated metastatic colorectal cancer.

Clinical Updates Wellness & Lifestyle

Routine Use of Cerebral Embolic Protection in TAVI: Evidence, Outcomes, and Clinical Implications

By MedXY 08/01/2025

Large-scale trials show that routine cerebral embolic protection during TAVI does not significantly reduce early stroke rates, though selective benefits in major stroke and secondary outcomes may exist.

Clinical Updates Wellness & Lifestyle

As-Needed Albuterol–Budesonide Therapy in Mild Asthma: Clinical Impact and Comparative Evidence

By MedXY 08/01/2025

As-needed albuterol–budesonide significantly reduces severe exacerbations in mild asthma compared to albuterol alone, with comparable safety. Two pivotal trials confirm efficacy across lung function and exacerbation outcomes.

Clinical Updates

Tenecteplase in Modern Stroke Care: Comparative Insights from Recent Chinese Clinical Trials

By MedXY 08/01/2025

Three major Chinese trials examine intravenous and intra-arterial tenecteplase as adjuncts to thrombectomy in acute large-vessel occlusion stroke, revealing functional benefit with intravenous use before thrombectomy but not after reperfusion.

Clinical Updates Wellness & Lifestyle

Inavolisib Improves Overall Survival in PIK3CA-Mutated Advanced Breast Cancer: Results from the INAVO120 Study

By MedXY 08/01/2025

Inavolisib combined with palbociclib and fulvestrant significantly prolongs overall survival in patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, but increases certain toxicities.